Evidence map›Paper›PMID 39602251›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Wenjing Xu, Yifan Sun, Peter Breen, Gary Ruvkun, Kai Mao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. The importance of IP6 for ADAR RNA-editing enzymes and antiviral defense.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Wenjing XuInstitute of Future Agriculture, Northwest Agriculture and Forestry University, Yangling, Shaanxi 712100, China.
Yifan SunInstitute of Future Agriculture, Northwest Agriculture and Forestry University, Yangling, Shaanxi 712100, China.
Peter BreenDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.
Gary RuvkunDepartment of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114.ORCID 0000-0002-7473-8484
Kai MaoInstitute of Future Agriculture, Northwest Agriculture and Forestry University, Yangling, Shaanxi 712100, China.

Funding

CONTROL OF THE C ELEGANS LINEAGE BY HETEROCHRONIC GENESR01GM044619 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1991 to 2026
$14.5M
GENETIC AND MOLECULAR BASIS OF LONGEVITYR01AG016636 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GARY B RUVKUN · 1999 to 2026
$12.4M
Genetic and Molecular Basis of LongevityR56AG016636 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RUVKUN, GARY B · 2021 to 2021
$344k
HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM044619HHS | NIH | National Institute on Aging (NIA) AG016636MOST | National Natural Science Foundation of China (NSFC) 32370811Natural Science Foundation of Shenzhen Municipality (Shenzhen Natural Science Foundation) JCYJ20230807111503008NIA NIH HHS R01 AG016636NIA NIH HHS R56 AG016636NIGMS NIH HHS R01 GM044619
6 · The paper itself

Abstract

RNA interference (RNAi) is an evolutionarily conserved pathway that defends against viral infections in diverse organisms.

Indexed as

Caenorhabditis elegansCaenorhabditis elegans ProteinsPhytic AcidRNA InterferenceAnimalsMutationPhosphotransferases (Alcohol Group Acceptor)Caenorhabditis elegans ProteinsPhosphotransferases (Alcohol Group Acceptor)Phytic Acidadenosine deaminaseinositol hexaphosphateRNAi interferenceunfolded protein response

Identifiers

PMID39602251
PMCPMC11626161

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.